NanoString Technologies Inc. Offers New Tool for Analyzing 25 Leukemia Fusion Genes in a Single Reaction

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the availability of a comprehensive multiplexed assay for the simple and cost-effective analysis of fusion genes linked to leukemia. The new tool is expected to greatly aid the ability of cancer researchers to characterize these genetic abnormalities.
MORE ON THIS TOPIC